Application of RIPK1 O-GlcNAc glycosylation inhibitor in preparation of medicine for enhancing Sunitinib sensitivity of renal cell carcinoma

By inhibiting RIPK1 O-GlcNAc glycosylation, the sensitivity of renal cell carcinoma to sunitinib was improved, and the problem of renal cell carcinoma resistance to drugs was solved, which significantly improved the therapeutic effect and provided biomarkers for clinical treatment. refer to.

CN119064582AActive Publication Date: 2024-12-03NANFANG HOSPITAL OF SOUTHERN MEDICAL UNIV

Patent Information

Application Number
CN202411221674.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-02
Publication Date
2024-12-03
Estimated Expiration
2044-09-02

AI Technical Summary

Technical Problem

The problem of drug resistance of renal cell carcinoma to sunitinib is that about 30% of patients develop metastatic renal cell carcinoma after treatment, and the prior art is difficult to effectively improve drug sensitivity.

Method used

RIPK1 O-GlcNAc glycosylation inhibitors or interfere with O-GlcNAc glycosylation levels in serine threonine kinase 1 (RIPK1), especially at Ser331, Ser440 and Ser669 sites -GlcNAc transferase expression, combined with sunitinib treatment, improves the sensitivity of renal cell carcinoma to drugs.

Benefits of technology

It significantly improves the sensitivity of renal cell carcinoma to sunitinib, extends the patient's survival, provides a reference for clinical treatment plans, and enhances the therapeutic effect of drugs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119064582A_ABST
    Figure CN119064582A_ABST
Patent Text Reader

Abstract

The invention provides an application of an RIPK1O-GlcNAc glycosylation inhibitor in preparation of a drug for enhancing the sensitivity of sunitinib to renal cell carcinoma. According to the application, the RIPK1O-GlcNAc glycosylation, particularly the O-GlcNAc glycosylation of serine at the 331 site, the 440 site and the 669 site, reduces the sensitivity of the renal cell carcinoma to the sunitinib. Therefore, by inhibiting the glycosylation of RIPK1O-GlcNAc or knocking down the expression of the O-GlcNAc transferase, the sensitivity of the renal cell carcinoma to the sunitinib is increased. Therefore, the O-GlcNAc glycosylation level of RIPK1 can be used as a biomarker for predicting the sensitivity of renal cell carcinoma to sunitinib; according to the present invention, the RIPK1O-GlcNAc glycosylation level is reduced by using the RIPK1O-GlcNAc glycosylation inhibitor, particularly the O-GlcNAc glycosylation of the 331 site, the 440 site and the 669 site serine is reduced, such that the sensitivity of the renal cell carcinoma to the sunitinib is increased, and the treatment effect of the sunitinib is improved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application relates to the field of biomedicine technology, and in particular to the use of a RIPK1 O-GlcNAc glycosylation inhibitor in the preparation of a drug for enhancing the sensitivity of renal cell carcinoma to sunitinib. Background Art

[0002] Renal cell carcinoma (RCC) is one of the most common malignancies worldwide, with an increasing incidence over the past two decades. Clear cell renal cell carcinoma (ccRCC) is the most common histological type, accounting for approximately 75% of RCC cases. Although advances have been made in the early diagnosis of renal cell carcinoma, approximately 30% of renal cell carcinoma patients have already developed distant metastases at the time of diagnosis, and approximately 30% of patients with localized and locally advanced renal cell carcinoma develop metastatic renal cell carcinoma (mRCC) after surgical treatment.

[0003] Tyrosine kinase inhibitors (TKIs) are promising drugs for the treatment of mRCC, which greatly prolong the survival of patients. However, most mRCC patients develop resistance to sunitinib after 6-11 months of treatment. Summary of the invention

[0004] The present application provides an application of a RIPK1 O-GlcNAc glycosylation inhibitor in the preparation of a drug for enhancing the sensitivity of renal cell carcinoma to sunitinib to solve the problems existing in the related technology. The technical solution is as follows:

[0005] In a first aspect, an embodiment of the present application provides a use of a reagent for detecting the O-GlcNAc glycosylation level of a biomarker RIPK1 in the preparation of a product for predicting the resistance of renal cell carcinoma to sunitinib.

[0006] In one embodiment, the O-GlcNAc glycosylation level of one or more of Ser331, Ser440 or Ser669 in the biomarker RIPK1 is detected.

[0007] In a second aspect, the embodiments of the present application provide a use of a RIPK1 O-GlcNAc glycosylation inhibitor in the preparation of a drug for enhancing the sensitivity of renal cell carcinoma to sunitinib.

[0008] In one embodiment, the inhibitor inhibits O-GlcNAcylation of one or more of Ser331, Ser440, or Ser669 in RIPK1.

[0009] In one embodiment, the inhibitor directly inhibits O-GlcNAcylation of RIPK1;

[0010] and / or;

[0011] Inhibition of O-GlcNAcylation of RIPK1 by inhibiting the production or expression of O-GlcNA transferase.

[0012] In one embodiment, the inhibitor is OSMI-1 and / or a lentiviral vector that interferes with O-GlcNAc transferase.

[0013] In one embodiment, the sequence of the lentiviral vector interfering with O-GlcNAc transferase is 5'-GGAGACAAGAGCCAGACAATA-3'.

[0014] In a third aspect, an embodiment of the present application provides a pharmaceutical composition for treating renal cell carcinoma, characterized in that it comprises sunitinib and any one of the above-mentioned inhibitors.

[0015] In one embodiment, the pharmaceutical composition further comprises a pharmaceutically acceptable carrier and / or a pharmaceutically acceptable excipient.

[0016] In one embodiment, the dosage form of the drug includes tablets, capsules, oral liquids, granules, suspensions, injections, powder injections, pellets, sustained-release agents, controlled-release agents or targeted preparations.

[0017] The advantages or beneficial effects of the above technical solution include at least:

[0018] 1. This application specifically studies the resistance of renal cell carcinoma to sunitinib, and finds that O-GlcNAc glycosylation of receptor interacting serine threonine kinase 1 (RIPK1), especially O-GlcNAc glycosylation of serine at positions 331, 440, and 669, reduces the sensitivity of renal cell carcinoma to sunitinib. This application finds that the total O-GlcNAc glycosylation level is significantly upregulated in sunitinib-resistant patients, and by inhibiting the O-GlcNAc glycosylation of RIPK1 or knocking down the expression of O-GlcNAc transferase, the sensitivity of renal cell carcinoma to sunitinib is increased. Therefore, the O-GlcNAc glycosylation level of RIPK1 can be used as a biomarker to predict the sensitivity of RCC to sunitinib, thereby providing a reference for the selection of clinical RCC treatment options.

[0019] 2. The pharmaceutical composition for treating renal cell carcinoma of the present application reduces the level of RIPK1 O-GlcNAc glycosylation by using a RIPK1 O-GlcNAc glycosylation inhibitor, especially reduces the OO-GlcNAc glycosylation of serine at positions 331, 440 and 669, thereby increasing the sensitivity of RCC to sunitinib and improving the therapeutic effect of sunitinib.

[0020] The above summary is for illustrative purposes only and is not intended to be limiting in any way. In addition to the illustrative aspects, embodiments and features described above, further aspects, embodiments and features of the present application will be readily apparent by reference to the accompanying drawings and the following detailed description. BRIEF DESCRIPTION OF THE DRAWINGS

[0021] In the accompanying drawings, unless otherwise specified, the same reference numerals throughout the multiple drawings represent the same or similar parts or elements. These drawings are not necessarily drawn to scale. It should be understood that these drawings only depict some embodiments disclosed in the present application and should not be regarded as limiting the scope of the present application.

[0022] Figure 1 Schematic diagram of the xenograft model established for sunitinib resistance;

[0023] Figure 2 Principal component analysis of non-targeted metabolic analysis of sunitinib-sensitive and -resistant tumors;

[0024] Figure 3 This is the expression level diagram of metabolites related to the HBP pathway of glucose metabolism;

[0025] Figure 4 Western blot of O-GlcNAc glycosylation in sunitinib-sensitive and -resistant renal cancer tissues;

[0026] Figure 5 This is an immunohistochemistry (IHC) test in sunitinib-sensitive and -resistant renal cancer tissues;

[0027] Figure 6 The results are for IC50 determination in sunitinib-sensitive and -resistant renal cancer cell lines;

[0028] Figure 7 Crystal violet staining of sunitinib-sensitive and -resistant renal cancer cells treated with sunitinib or control;

[0029] Figure 8 Western blot and content of total O-GlcNAc glycosylation in sunitinib-sensitive and -resistant renal cancer cells;

[0030] Fig. 9 Representative bright field images and crystal violet staining images of Caki-1, 786O and ACHN cells exposed to sunitinib (with or without OSMI-1); A is a representative bright field image of Caki-1, 786O and ACHN cells exposed to sunitinib (with or without OSMI-1); B is a crystal violet staining image of Caki-1, 786O and ACHN cells exposed to sunitinib (with or without OSMI-1);

[0031] Fig.10 The apoptosis rate of Caki-1, 786O and ACHN cells exposed to sunitinib (with or without OSMI-1) was detected using CCK8;

[0032] Fig.11 Figure 2 shows the apoptosis of 786O and ACHN cells exposed to sunitinib with or without OSMI-1 analyzed by flow cytometry.

[0033] Fig.12 The graphs are for detecting the levels of apoptosis markers activated Caspase-3, activated Caspase8 and activated PARP in Caki-1, 786O and ACHN cells in the presence or absence of OSMI-1 and sunitinib by Western blotting; A is for Caki-1, 786O and ACHN cells without OSMI-1; B is for Caki-1, 786O and ACHN cells with OSMI-1;

[0034] Fig.13 This is an in vivo xenograft experiment, showing the tumor status of mice; A is the appearance picture; B is the volume change picture; C is the weight comparison picture.

[0035] Fig.14 This is the IHC image of mouse tumors in the in vivo xenograft experiment;

[0036] Fig.15 This is the result of TUNEL detection of mouse tumors in in vivo xenograft experiments;

[0037] Fig.16 The results of IHC detection of two key enzymes in RCC tissues that are sensitive and resistant to sunitinib are shown;

[0038] Fig.17 Western blot of OGT in sunitinib-sensitive and -resistant RCC cells;

[0039] Fig.18 IF staining images of OGT in sunitinib-sensitive and -resistant RCC cells;

[0040] Fig.19 Western blot of OGT protein expression in RCC cells after sunitinib treatment;

[0041] Fig. 20 This is the survival analysis diagram of TCGA-KIRC dataset based on OGT;

[0042] Fig.21 The results of down-regulating OGT expression by shRNA are shown in Figure 1; A is a Western blot of O-GlcNA; B is a Sunitinib sensitivity graph; C is a Sunitinib-induced apoptosis graph; D is a Western blot of the expression of apoptosis markers;

[0043] Fig. 22 This is an in vivo xenograft experiment of OGT knockout, showing the tumor status of mice; A is the appearance; B is the volume change; C is the weight comparison;

[0044] Fig.23 This is the IHC staining picture of the OGT knockout in vivo xenograft experiment;

[0045] Fig.24 The HA-tagged OGT plasmid was transfected into 293T cells with or without Myc-tagged RIPK1 plasmid, and the exogenous CoIP results were performed;

[0046] Fig.25 Figure 1 shows the results of endogenous CoIP assay using anti-RIPK1 antibody;

[0047] Fig.26 The 3D model diagram of OGT / RIPK1 interaction was predicted using HDOCK software;

[0048] Fig. 27 Western blot of O-GlcNAc glycosylation in 293T cells co-transfected with Flag-tagged RIPK1 plasmid and different concentrations of HA-tagged OGT plasmid;

[0049] Fig.28 Graphs showing the results of CoIP assays; A is a graph showing the results of assays using anti-O-GlcNAc antibodies; B is a graph showing the results of CoIP assays using anti-Flag antibodies; and C is a graph showing the results of K.CoIP assays using anti-O-GlcNAc antibodies.

[0050] Fig.29 Schematic diagram for constructing full-length and truncated HA-tagged OGT plasmids;

[0051] Fig.30 The figure shows the results of CoIP assay using anti-Flag antibody on HA-tagged full-length OGT and truncated genes co-transfected with Flag-tagged RIPK1 in 293T cells;

[0052] Fig.31 Schematic diagram for constructing full-length and truncated Myc-tagged OGT plasmids;

[0053] Fig.32 The figure shows the results of CoIP assay using anti-HA antibody on 293T cells co-transfected with Myc-tagged full-length RIPK1 and truncated fragments and HA-tagged OGT;

[0054] Fig.33 Schematic diagram of the prediction of potential O-GlcNAc glycosylation sites of RIPK1 by the online database YinOYang;

[0055] Fig.34 RIPK1 constructed for Sanger sequencing pairs WT , RIPK1 S331A , RIPK1 S440A and RIPK1 S669A and RIPK1 3A Plasmids were sequence verified;

[0056] Fig.35 The results of CoIP determination of the O-GlcNAc site of RIPK1, wherein A is the potential O-GlcNAc glycosylation site of RIPK1 verified by anti-Flag antibody; B is the potential O-GlcNAc glycosylation site of RIPK1 verified by anti-O-GlcNac antibody;

[0057] Fig.36 CoIP assay was used to verify the potential O-GlcNAc glycosylation sites of RIPK1 with OSMI-1 and TMG;

[0058] Fig.37 The results of CoIP assay, where A is used to verify the stable expression of RIPK1 WT or RIPK1 3A Potential O-GlcNAc glycosylation sites of RIPK1 in Caki-1 cells; B is the stable expression of RIPK1 after sunitinib treatment WT RIPK1 3A Crystal violet staining of Caki-1 cells;

[0059] Fig.38 After sunitinib treatment, cells stably expressed RIPK1 WT or RIPK1 3A Figure 1 shows the results of Caki-1 cell CCK8 assay;

[0060] Fig.39 Stable expression of RIPK1 after sunitinib treatment WT or RIPK1 S331A Western blot detection of apoptosis markers in Caki-1 cells;

[0061] Fig.40 CoIP was performed to detect the stability of RIPK1 / FADD / Caspase-8 complex in sunitinib-sensitive and -resistant renal cell carcinoma cells;

[0062] Fig.41. The effects of OSMI-1 inhibitor and OGT knockout on the formation of RIPK1 / FADD / Caspase-8 complex, wherein A is the effect of using OSMI-1 to inhibit O-GlcNAc glycosylation on the formation of RIPK1 / FADD / Caspase-8 complex; B is the effect of using shOGT to inhibit O-GlcNAc glycosylation on the formation of RIPK1 / FADD / Caspase-8 complex;

[0063] Fig.42 To stably express RIPK1 WT RIPK1 3A Effect of RIPK1-O-GlcNAc glycosylation on the formation of RIPK1 / FADD / Caspase-8 complex in Caki-1 cells;

[0064] Fig.43 To detect whether NF-κB was activated after sunitinib treatment by Western blotting;

[0065] Fig.44 The results of IF assay for sunitinib-induced P65 nuclear localization;

[0066] Fig.45 Schematic diagram of O-GlcNAc glycosylation regulation of RIPK1-dependent apoptosis. DETAILED DESCRIPTION

[0067] In the following, only some exemplary embodiments are briefly described. As those skilled in the art will appreciate, the described embodiments may be modified in various ways without departing from the spirit or scope of the present application. Therefore, the drawings and descriptions are considered to be exemplary and non-restrictive in nature.

[0068] Example 1

[0069] 1. Materials and Methods

[0070] 1. Materials

[0071] Cell culture

[0072] RCC cell lines (Caki-1, 786O and ACHN) and human embryonic kidney cell line 293T cells were purchased from the American Type Culture Collection (ATCC). Caki-1, ACHN and 293T cells were cultured in DMEM medium (Gibco). 786O cells were cultured in RPMI 1640 medium (Gibco). All culture media were supplemented with 10% fetal bovine serum (Haixing, Suzhou) and 1% penicillin / streptomycin (New Cell & Molecular Biotech, Suzhou) to maintain cell growth.

[0073] 1.2. Antibodies, inhibitors and chemicals

[0074] The following commercial antibody inhibitors and chemicals were used in this study: anti-O-GlcNAc (#12938, CST; #59623, Santa Cruz; #PTM-951RM, PTM-BIO), anti-caspase-3 (#14220, CST), anti-cleavedcaspase-3 (#25128-1-AP, Protei nTech),anti-caspase-8(#9746,CST),anti-cleavedcaspase-8(#9496,CST),anti-PARP(#9542,CST),anti- OGT(#24083,CST;#ab96718,Abcam),anti-OGA(#ab105217,Abcam),anti-RIPK1(#3493,CST),anti-HA-tag(# 3724,CST),anti-Myc-tag(#2278,CST),anti-Flag-tag(#66008-4,ProteinTech),anti-FADD(#271748,Santa Cruz),anti-ubiquitination(#10201-2-AP,ProteinTech),anti-CYLD(#8462,CST),anti-A20(#5630,CST),anti-cIAP1(#7065,CST),anti-cIAP2(#3031,CST),anti-GAPDH(#60004-1,ProteinTech),HA agarose(#A2095,Sigma-Aldrich),Myc agarose(#A7470,Sigma-Aldrich),Flag agarose(#A2220,Sigma-Aldrich),Sunitinib(#7781,Selleck),Z-VAD-FMK(#7023,Selleck),Necrostatin-1(#8037,Selleck)andFerrostatin-1(#7243,Selleck),OSMI-1(#9835,Selleck),Thiamet G(HY12588,MedChemExpress),CHX(#7418,Selleck)and MG132(#2619,Selleck).

[0075] 2. Methods

[0076] 2.1. Establishment of drug-resistant cell lines

[0077] Sunitinib-sensitive and sunitinib-resistant renal cell carcinoma cell lines were cultivated by stepwise selection. The RCC cell lines were cultured in a medium containing sunitinib for 2 weeks and in a medium without sunitinib for another week; the concentration of sunitinib was gradually increased (2-10μM) in each round; the entire culture process lasted about 10 months, and finally sunitinib-resistant RCC cell lines were obtained and named Caki-1-R, 786O-R and ACHN-R. The sensitivity of these cell lines was evaluated by testing the IC50 value of sunitinib. .

[0078] 2.2. Construction of sunitinib-sensitive and sunitinib-resistant renal cell carcinoma models in mice

[0079] About 5.0×10 6 Caki-1 cells were injected subcutaneously into the upper back of 6-week-old BALB / c nude mice. When the volume of the first generation tumor reached 200 mm 3 At the same time, mice were given sunitinib or saline according to the standard regimen (40 mg / kg / day, oral administration for 4 weeks, and oral administration was suspended for 2 weeks). After the treatment course, the first generation tumors were surgically isolated and cut into 1 mm 3 Then these 1mm 3 The tumor pieces were transplanted into the second generation mice and treated with saline or sunitinib. The third generation mice were finally sacrificed and the sunitinib-sensitive and -resistant renal cell carcinoma tissues were surgically isolated for further experiments. Figure 1 shown.

[0080] Plasmids

[0081] The full-length human RIPK1, truncated RIPK1 (RIPK1 WT , RIPK1 DD , RIPK1 △DD , RIPK1 KD , RIPK1 △KD and RIPK1 ID ) and mutant RIPK1 S331A , RIPK1 S440A , RIPK1 S669A and RIPK1 3A The sequences were subcloned into pcDNA3-Flag or pcDNA3-Myc vectors.

[0082] The full-length human OGT and the truncated OGT (OGT WT 、OGT TPR、OGT TPR-NLS 、OGT △TPR and OGT △CAT ) and the mutant OGT sequence (OGT K852R and OGT K908R ) were subcloned into the pcDNA3-HA vector.

[0083] Using pcDNA3-RIPK1 as a template, wild-type RIPK1 and mutant RIP K1 were subcloned into a lentiviral vector containing an N-terminal Flag tag to obtain lentiviral vectors expressing wild-type RIPK1 and mutant RIPK1. All products cloned by DNA were verified by Sanger sequencing (Tsingke Biotch, Beijing); lentiviral shRNAs for OGT were purchased from IGE Biotechnology (Guangzhou, China).

[0084] 2.4. Liquid chromatography-tandem mass spectrometry (LC-MS / MS)

[0085] Non-targeted metabolome analysis was performed using LC-MS / MS technology at Shanghai Zhongke Xinsheng Biotechnology Co., Ltd. to identify metabolic changes in sunitinib-sensitive and sunitinib-resistant renal cell carcinoma tumors; OGT-binding proteins were identified by co-immunoprecipitation in renal cell carcinoma cells Caki-1 and Caki-1-R using anti-OGT antibodies or IgG; proteins enriched in anti-OGT antibodies were separated by polyacrylamide gel electrophoresis and silver stained, and bound proteins were analyzed by mass spectrometry.

[0086] 2.5. Cell transfection and lentiviral infection

[0087] Plasmids were transfected into RCC cell lines using Lipofectamine 3000 transfection reagent (Invitrogen) according to the instructions. Plasmids were transfected into 293T cells using PEI transfection reagent (Polysciences) according to the instructions. For lentiviral infection, 293T cells were transfected with packaging vectors (pMD2.G and psPAX2) and GFP shRNA or OGT shRNA, and infected viral particles were collected. Viral particles were added to the culture medium together with 10 μg / ml polyethyleneimine (Beyotime) and incubated with cells for 8 hours. Afterwards, stably expressing cell lines and control cells were selected using puromycin.

[0088] Western blotting

[0089] RCC cells were lysed using EBC buffer (50 mM Tris, 120 mM NaCl, 0.5% NP-40) or RIPA lysis buffer (Cell Signaling Technology) with a protease / phosphatase inhibitor cocktail (New Cell & Molecular Biotech, Suzhou). Equal amounts of protein extracts were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gel separation. After separation, the proteins were transferred to polyvinylidene fluoride (PVDF) membranes, and the PVDF membranes were blocked using TBST buffer containing 5% bovine serum albumin (BSA) to prevent nonspecific binding. The blocked PVDF membranes were then incubated with specific primary antibodies overnight at 4 °C, and secondary antibodies were labeled with horseradish peroxidase (HRP). Finally, the protein bands were visualized using the GelView 6000Pro imaging system from BLT (China).

[0090] Flow cytometry

[0091] Flow cytometric analysis was used to evaluate the role of O-GlcNAc glycosylation or OGT on apoptosis of RCC cells during sunitinib treatment. The role of O-GlcNAc glycosylation was explored by inhibiting overall O-GlcNAc glycosylation using the small molecule inhibitor OSMI-1. In addition, to explore the role of OGT, RCC cells were transfected with shNC or shOGT, and these cells were collected after 48 hours of treatment with sunitinib. Subsequently, they were washed with PBS, first stained with Annexin V-FITC, then stained with PI, and finally the apoptosis rate of RCC cells was detected using a FACS flow cytometer (Becton Dickinson).

[0092] Immunohistochemistry

[0093] Immunohistochemistry was performed on renal cell carcinoma tissues to detect and visualize specific proteins. First, 4-μm-thick RCC tissue sections were dewaxed and dehydrated in preparation for antibody staining. Tissue sections were treated with 3% hydrogen peroxide for 10 minutes at room temperature to inhibit endogenous peroxidase activity. Next, the sections were blocked with 5% BSA for 30 minutes at room temperature to reduce nonspecific binding of antibodies. Subsequently, the sections were incubated with rabbit or mouse antibodies specific for the target protein at 4°C overnight. The next day, the sections were washed three times with PBS to remove unbound primary antibodies, and then the sections were incubated with secondary antibodies at 37°C for 1 hour. After washing, the tissue sections were stained with 3,3'-diaminobenzidine substrate, and images of the stained tissue sections were acquired using an upright microscope (Olympus, Japan).

[0094] 2.9. Immunofluorescence and confocal microscopy

[0095] First, RCC cells were fixed with 4% paraformaldehyde for 15 minutes. After fixation, cells were treated with 0.1% TritonX-100 for 15 minutes at room temperature to increase cell membrane permeability. To avoid nonspecific binding, cells were blocked with 5% BSA for 1 hour at room temperature. Then, cells were incubated with specific antibodies overnight at 4°C. The next day, cells were washed three times with PBS to remove unbound primary antibodies. Next, cells were incubated with the corresponding secondary conjugated antibodies for 1 hour at room temperature. Finally, cell nuclei were stained with DAPI, and the stained cells were imaged using an Olympus (Tokyo, Japan) confocal microscope.

[0096] 2.10. Co-immunoprecipitation (CoIP) assay

[0097] About 1×10^7 cells were collected and lysed using EBC buffer containing a protease / phosphatase mixture; 5% of the cell lysate was reserved as a positive control. For endogenous CoIP detection, the remaining cell lysate was incubated with the primary antibody overnight at 4°C. Subsequently, the lysate was incubated with protein A / G immunomagnetic beads at 4°C for 6 hours. For exogenous CoIP antibodies, the remaining cell lysate was incubated with anti-HA affinity gel (Sigma-Aldrich, Germany), anti-Flag affinity gel (Yeasen, Shanghai) or anti-Myc affinity gel (Sigma-Aldrich, Germany). After incubation, the immune complex was washed three times with NETN buffer (20mM Tris, 100mM NaCl, 1mM EDTA, 0.5% NP-40) to remove non-specifically bound proteins and ensure the specificity of subsequent steps. Then, the protein was eluted from the magnetic beads with loading buffer under standard denaturing conditions, and the purified protein was detected by Western blotting.

[0098] Xenograft tumor models

[0099] 5×10 6 Caki-1 cells were injected subcutaneously into the upper back of nude mice (BALB / c, 6 weeks old, n = 6 per group). Mice were treated with sunitinib or saline orally according to the standard regimen (40 mg / kg / day) and the tumor volume reached 200 mm 3 ; After 4-6 weeks, the mice were killed and the tumor tissues were removed for analysis.

[0100] Statistics

[0101] The Student t test was used to compare the differences in gene expression between two groups; analysis of variance was used to compare the differences in gene expression among multiple groups; the log-rank test was used to assess survival differences; all statistical tests were two-sided.

[0102] 2. Conclusion

[0103] 1.1. O-GlcNAcylation is significantly upregulated in sunitinib-resistant renal cell carcinoma

[0104] Nontargeted metabolic profiling of sunitinib-sensitive and sunitinib-resistant tumors was performed using liquid chromatography-tandem mass spectrometry (LC-MS / MS). Figure 2 As shown:

[0105] from Figure 2 The principal component analysis results showed significant changes in metabolic signatures between sunitinib-sensitive and sunitinib-resistant tumors.

[0106] For changes in glucose metabolism, such as Figure 3 As shown, the abundance of two key metabolites in the glycosamine biosynthesis pathway (HBP), D-glucosamine 6-phosphate (GlcN-6-P) and uridine diphosphate N-acetylglucosamine (UDP-GlcNAc), was significantly increased in sunitinib-resistant tumors; and the UDP-GlcNAc produced by HBP is the donor substrate for O-GlcNAc glycosylation modification, indicating that the level of O-GlcNAc glycosylation may be increased in sunitinib-resistant tumors.

[0107] Western and immunohistochemistry (IHC) tests were performed, and the results were as follows Figure 4 and Figure 5 As shown, from Figure 4 and Figure 5 The results showed that the total O-GlcNAcylation level was significantly upregulated in the sunitinib-resistant RCC group compared with the sunitinib-sensitive RCC tissues.

[0108] Sunitinib-resistant RCC cells (Caki-1-R, ACHN-R, and 786O-R) established by repeated induction of sunitinib treatment showed significantly increased sunitinib IC50 values ​​in sunitinib-resistant RCC cells (Caki-1-R, ACHN-R, and 786O-R) compared with sunitinib-sensitive RCC cells (Caki-1, ACHN, and 786O), as shown in Figure 3 Figure 6 and Figure 7 shown.

[0109] The total O-GlcNAc glycosylation levels in sunitinib-sensitive and -resistant RCC cells were detected simultaneously. The total O-GlcNAc glycosylation levels in resistant RCC cells were significantly upregulated compared with those in sensitive RCC cells (Caki-1-R, ACHN-R, and 786O-R). Figure 8 .

[0110] Therefore, the above detection revealed that O-GlcNAc glycosylation was significantly upregulated in sunitinib-resistant renal cell carcinoma.

[0111] 2.2 Inhibition of O-GlcNAcylation can enhance sunitinib-induced apoptosis in renal cell carcinoma cells

[0112] The small molecule inhibitor OSMI-1 was used to inhibit global O-GlcNAcylation. Fig. 9 and Fig.10 As shown, from Fig. 9 Representative bright-light images of Caki-1, 786O, and ACHN cells exposed to sunitinib with or without OSMI-1 in A and Fig. 9 B is the crystal violet staining image of Caki-1, 786O and ACHN cells exposed to sunitinib (with or without OSMI-1) and Fig.10 Using CCK8 to detect the apoptosis rate of Caki-1, 786O and ACHN cells exposed to sunitinib (with or without OSMI-1), it can be seen that inhibition of O-GlcNAcylation by OSMI-1 significantly increased sunitinib-induced RCC cell death.

[0113] Flow cytometry showed that inhibition of O-GlcNAcylation significantly increased sunitinib-induced apoptosis in RCC cells. Fig.11 .

[0114] After sunitinib treatment, Caki-1, 786O, and ACHN cells were treated with sunitinib with or without OSMI-1; the levels of apoptotic markers including activated Caspase-3, activated Caspase8, and activated PARP were detected by Western blotting. Fig.12 As shown. Fig.12 It can be seen that inhibition of O-GlcNAcylation significantly increased the expression of apoptotic markers including activated Caspase-3, activated Caspase8, and activated PARP.

[0115] For further in vivo xenograft experiments, 1×10 6Caki-1 cells were injected subcutaneously into each nude mouse (n=5); mice were orally treated with sunitinib, saline, or a combination of OSMI-1 and sunitinib according to the standard regimen (40 mg / kg / day). Mice were killed 4 weeks later and tumor tissues were removed for imaging analysis. Fig.13 As shown, Fig.13 A is the appearance picture; Fig.13 B is the volume change diagram; Fig.13 C is a weight comparison chart; IHC Fig.14 As shown; TUNEL detection results are shown Fig.15 shown.

[0116] from Fig.13 It can be seen that OSMI-1 inhibited O-GlcNAc glycosylation and significantly improved the efficacy of sunitinib in the treatment of renal cell carcinoma; the sunitinib combined with OSMI-1 inhibitor group significantly inhibited tumor growth, and the tumor size was smaller and lighter than that of the sunitinib group.

[0117] Fig.14 IHC analysis showed that the activated Caspase-3 was significantly increased in the sunitinib combined with OSMI-1 inhibitor group compared with the sunitinib group. Fig.15 The TUNEL assay results further showed that the proportion of apoptotic cells was the highest in the sunitinib combined with OSMI-1 inhibitor group.

[0118] The effects of the above-mentioned OSMI-1 inhibitors indicate that inhibition of O-GlcNAc glycosylation can increase sunitinib-induced apoptosis in renal cell carcinoma cells.

[0119] 2.3. OGT knockout increases sunitinib sensitivity in patients with renal cell carcinoma

[0120] O-GlcNAc transferase (OGT) and GlcNAcase (OGA) control the dynamic cycle of O-GlcN acylation modification; IHC detection of the above two key enzymes in sunitinib-sensitive and -resistant RCC cells showed the following results: Fig.16 As shown. Fig.16 As can be seen, OGT, but not OGA, is upregulated in sunitinib-resistant renal cell carcinoma. It was also determined by Western blotting that OGT was upregulated in sunitinib-resistant RCC cells compared with sunitinib-sensitive RCC cells. Fig.17 Using immunofluorescence (IF) detection, OGT was also significantly upregulated in sunitinib-resistant RCC cells. Fig.18 .

[0121] Subsequently, RCC cells sensitive to sunitinib were continued to be given sunitinib, and the expression of OGT in renal cell carcinoma cells after 6h, 12h, and 24h of sunitinib treatment was determined by Western blotting. Fig.19 As shown, from Fig.19 It can be seen that the expression of OGT in renal cell carcinoma cells increased with the increase of sunitinib treatment time.

[0122] Gene expression profile interactive analysis (GEPIA) was used to evaluate the prognostic outcome of OGT in renal cell carcinoma tissues. Fig. 20 The results showed that the survival time of RCC patients with high OGT expression was shorter than that of patients with low OGT expression.

[0123] For RCC cells, OGT expression was downregulated by shRNA. Fig.21 As shown, Fig.21 A is a Western blot of O-GlcNA; Fig.21 B is the sunitinib sensitivity graph; Fig.21 C is a graph of cell apoptosis induced by sunitinib; Fig.21 D is a Western blot of the expression of apoptosis markers.

[0124] Fig.21 The results showed that Western blotting determined the total O-GlcNAc glycosylation level, and OGT knockout significantly reduced the total O-GlcNAc glycosylation in RCC cells; OGT knockout significantly increased the sensitivity of RCC cells to sunitinib; flow cytometry showed that OGT downregulation significantly increased sunitinib-induced RCC cell apoptosis; in addition, the expression of activated Caspase-3, activated Caspase8 and activated PARP in shOGTRCC cells was significantly increased after sunitinib treatment.

[0125] Further in vivo xenograft experiments were performed; 1×10 6 Each nude mouse (n=5) was subcutaneously injected with shNC or shOGT Caki-1 cells. The mice were orally treated with sunitinib, saline, or a combination of OSMI-1 and sunitinib according to the standard regimen (40 mg / kg / day). The mice were killed 4 weeks later and the tumor tissues were removed for imaging analysis. The tumor conditions were as follows: Fig. 22 As shown, Fig. 22 A is the appearance picture; Fig. 22 B is the volume change diagram; Fig. 22 C is a weight comparison chart; IHC Fig.23 As shown, it is obvious that OGT knockout significantly improved the efficacy of sunitinib; IHC detection showed that the expression of activated Caspase-3 in shOGT RCC tissues was significantly increased.

[0126] Therefore, OGT-mediated O-GlcNAcylation plays an important role in sunitinib sensitivity and OGT knockout improves the therapeutic effect of sunitinib.

[0127] 2.4. OGT specifically interacts with RIPK1 and promotes RIPK1 O-GlcNAcylation

[0128] HA-tagged OGT plasmid was transfected into 293T cells with or without Myc-tagged RIPK1 plasmid, and exogenous CoIP assay was performed. The results are shown in Fig.24 Exogenous CoIP assay in 293T confirmed the direct interaction between OGT and RIPK1 ( Figure 4 DE).

[0129] Endogenous CoIP assay was performed using anti-RIPK1 antibody, and the results were as follows Fig.25 Endogenous CoIP assays in RCC cells showed that OGT specifically interacted with RIPK1, and this interaction was enhanced in sunitinib-resistant RCC Caki-1-R. The 3D model of the OGT / RIPK1 interaction was predicted using HDOCK software. Fig.26 The results show that OGT and RIPK1 directly interact with each other in sunitinib-sensitive and sunitinib-resistant RCC cells.

[0130] Flag-tagged RIPK1 plasmid and different concentrations of HA-tagged OGT plasmid were co-transfected into 293T cells, and the overall O-GlcNAc glycosylation level was detected by Western blotting. Fig. 27 As shown; the results showed that OGT significantly induced the overall O-GlcNAcylation level and RIPK1 O-GlcN acylation.

[0131] CoIP assay was further performed with anti-O-GlcNAc antibody or anti-Flag-RIPK1, as Fig.28 As shown in A, OGT significantly promoted RIPK1 O-GlcNAcylation; HA-tagged OGT (WT or mutant) and Flag-tagged RIPK1 plasmids were transfected into 293T cells, and CoIP assay was performed using anti-Flag antibody, as shown in Fig.28 As shown in B, O-GlcN glycosylation of RIPK1 depends on the enzymatic activity of OGT; consistent with the above results, K.CoIP assay using anti-O-GlcNAc antibody showed that RIPK1 O-GlcNAc glycosylation in sunitinib-resistant RCC cells was significantly increased compared with sunitinib-sensitive RCC cells, as shown in Fig.28 As shown in C.

[0132] Thus, OGT specifically interacts with RIPK1 and promotes RIPK1 O-GlcNAcylation.

[0133] 2.5.RIPK1 at Ser 331 , Ser 440 and Ser 669 Sensitivity of O-GlcNAcylation on β-lactamase to sunitinib

[0134] Build as Fig.29 The full-length and truncated HA-tagged OGT plasmids shown (based on their domain sequences, named HA-OGT WT HA-OGT TPR HA-OGT TPR-NLS HA-OGT △TPR and HA-OGT △CAT ).

[0135] The plasmid was co-transfected with the Flag-tagged RIPK1 plasmid into 293T cells for CoIP detection. Fig.30 As shown; indicating that the tetraterpene peptide repeat (TPR) domain of OGT directly interacts with RIPK1.

[0136] Similarly, constructing Fig.31 The full-length and truncated Myc-tagged RIPK1 (named Myc-RIPK1 based on its domain sequence) are shown. WT 、Myc-RIPK1 DD 、Myc-RIPK1 △DD 、Myc-RIPK1 KD 、Myc-RAPK1 △KD and Myc-RINK1 ID ), Fig.32 CoIP analysis showed that the middle (ID) domain of RIPK1 is essential for the interaction with OGT.

[0137] The potential sites for O-GlcNAc glycosylation on RIPK1 were predicted using the online database YinOYang (Gupta and Brunak, 2002). Fig.33 The results showed that Ser331, Ser440 and Ser669 of RIPK1 were likely to be modified by O-GlcNAc glycosylation.

[0138] Construction of Flag-tagged wild-type RIPK1 (RIPK1 WT ), single-site mutation RIPK1 S331A , RIPK1 S440A and RIPK1 S669Aand triple-point mutations in RIP K1 (RIPK1 3A ) plasmid and verified by Sanger sequencing. Fig.34 .

[0139] like Fig.35 As shown, WT Compared with single mutation (RIPK1 S331A , RIPK1 S440A and RIPK1 S669A ) moderately reduced the O-GlcNAcylation signal of RIPK1, while RIPK1 3A The O-GlcNAc glycosylation modification signal was significantly reduced.

[0140] Similarly, if Fig.36 As shown, OSMI-1 can reduce RIPK1 WT TMG can increase O-GlcNAc glycosylation, while they cannot affect RIPK1 3A This indicates that Ser 331, Ser 440, and Ser 669 are the key O-GlcNylation sites on RIPK1.

[0141] By stably expressing RIPK1 in Caki-1 cells WT or RIPK1 3A , Fig.37 Shows that RIPK1 WT In contrast, RIPK1 3A Significantly reduced the O-GlcNAc glycosylation modification signal in Caki-1 cells. WT In contrast, RIPK1 3A Significantly increased sunitinib-induced apoptosis in RCC cells, such as Fig.38 As shown, this suggests that O-GlcNAcylation of RIPK1 Ser 331, Ser 440, and Ser 669 reduces sunitinib sensitivity. Fig.39 Western blotting also showed that RIPK13A significantly increased activated Caspase-3, Caspase-8, and PARP in RCC cells after sunitinib treatment.

[0142] Thus, OGT specifically interacts with RIPK1 through its TPR domain and promotes O-GlcNAcylation of RIPK1 at Ser 331, Ser 440, and Ser 669, inhibiting sunitinib-induced apoptosis in RCC cells.

[0143] 2.6. O-GlcNAcylation affects the formation of RIPK1 / FADD / Caspase-8 complex and NF-κB activation

[0144] After sunitinib treatment, FADD was immunoprecipitated in sunitinib-sensitive and -resistant RCC cells, and RIPK1 and Caspase-8 were detected. Fig.40 As shown, the RIPK1 / FADD / Caspase-8 complex was significantly reduced in sunitinib-resistant RCC cells compared with sunitinib-sensitive RCC cells.

[0145] Fig.41 The effects of OSMI-1 inhibitor and OGT knockdown on the formation of RIPK1 / FADD / Caspase-8 complex were investigated. Fig.41 As shown in A, the inhibition of O-GlcNAc glycosylation by OSMI-1 inhibitors led to the formation of RIPK1 / FADD / Caspase-8 complex in RCC cells after sunitinib treatment, indicating that O-GlcNAc glycosylation regulates sunitinib sensitivity by affecting the RIPK1 / ADD / SCaspase-8 complex; Fig.41 As shown in B, the inhibition of O-GlcNAc glycosylation by OGT knockout significantly induced the formation of RIPK1 / FADD / Caspase-8 complex in RCC cells.

[0146] And, if Fig.42 As shown, stably expressing RIPK1 3A The RIPK1 / FADD / Caspase-8 complex was significantly increased in Caki-1 cells with WT Tgp1, indicating that O-GlcNAcylation of RIPK1 on Ser 331, Ser 440, and Ser 669 inhibited the formation of the RIPK1 / ADD / Caspase-8 complex.

[0147] Next, Western blotting was used to detect whether NF-κB was activated after sunitinib treatment, as shown in Fig.43 As shown, p-P65 was significantly induced in RCC cells after sunitinib treatment. p-P65 is an indicator of p65 activation and serves as a major transcription factor of the NF-κB signaling pathway, indicating that the NF-κB pathway is activated to activate the transcription of target genes, thereby maintaining cell survival after sunitinib treatment. Fig.44 The IF assay shown in Figure 2 showed that sunitinib treatment significantly induced the nuclear localization of P65, while the inhibition of O-GlcNAcylation by OSMI-1 significantly inhibited the sunitinib-induced nuclear localization of P65. Fig.45 .

[0148] In summary, the present application conducted a specific study on the resistance of renal cell carcinoma to sunitinib, and found that O-GlcNAc glycosylation of receptor interacting serine threonine kinase 1 (RIPK1), especially O-GlcNAc glycosylation of serine at positions 331, 440 and 669, reduced the sensitivity of renal cell carcinoma to sunitinib. By inhibiting the O-GlcNAc glycosylation of RIPK1 or knocking down the expression of O-GlcNA transferase, the sensitivity of renal cell carcinoma to sunitinib was increased. Therefore, the O-GlcNAc glycosylation level of RIPK1 can be used as a biomarker to predict the sensitivity of RCC to sunitinib, thereby providing a reference for the selection of clinical RCC treatment options. And by using RIPK1 O-GlcNAc glycosylation inhibitors to reduce the level of RIPK1 O-GlcNAc glycosylation, especially reducing the O-GlcNAc glycosylation of serine at positions 331, 440 and 669, thereby increasing the sensitivity of RCC to sunitinib and improving the therapeutic effect of sunitinib.

[0149] In the description of this specification, the description with reference to the terms "one embodiment", "some embodiments", "example", "specific example", or "some examples" means that the specific features, structures, materials or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the present application. Moreover, the specific features, structures, materials or characteristics described may be combined in any one or more embodiments or examples in a suitable manner. In addition, those skilled in the art may combine and combine different embodiments or examples described in this specification and the features of different embodiments or examples, unless they are contradictory.

[0150] In addition, the terms "first" and "second" are used for descriptive purposes only and should not be understood as indicating or implying relative importance or implicitly indicating the number of technical features indicated. Therefore, a feature defined as "first" or "second" may explicitly or implicitly include at least one of the features. In the description of this application, the meaning of "plurality" is two or more, unless otherwise clearly and specifically defined.

[0151] The above is only a specific implementation of the present application, but the protection scope of the present application is not limited thereto. Any technician familiar with the technical field can easily think of various changes or substitutions within the technical scope disclosed in the present application, which should be included in the protection scope of the present application. Therefore, the protection scope of the present application should be based on the protection scope of the claims.

Claims

1. Application of a reagent for detecting the O-GlcNAc glycosylation level of the biomarker RIPK1 in the preparation of a product for predicting the resistance of renal cell carcinoma to sunitinib.

2. The use according to claim 1, characterized in that: The O-GlcNAc glycosylation levels of one or more of Ser331, Ser440 or Ser669 in the biomarker RIPK1 are detected.

3. Application of RIPK1 O-GlcNAc glycosylation inhibitors in the preparation of drugs that enhance the sensitivity of renal cell carcinoma to sunitinib.

4. The use according to claim 3, characterized in that: The inhibitor inhibits O-GlcNAcylation of one or more of Ser331, Ser440 or Ser669 in RIPK1.

5. The use according to claim 3 or 4, characterized in that: The inhibitor directly inhibits O-GlcNAc glycosylation of RIPK1; and / or; Inhibition of O-GlcNAcylation of RIPK1 by inhibiting the production or expression of O-GlcNAc transferase.

6. The use according to claim 5, characterized in that: The inhibitor is OSMI-1 and / or a lentiviral vector interfering with O-GlcNAc transferase.

7. The use according to claim 6, characterized in that: The sequence of the lentiviral vector interfering with O-GlcNA transferase is 5'-GGAGACAAGAGCCAGACAATA-3'.

8. A pharmaceutical composition for treating renal cell carcinoma, characterized in that: The invention comprises sunitinib and the inhibitor according to any one of claims 3 to 7.

9. A pharmaceutical composition for treating renal cell carcinoma according to claim 8, characterized in that: The pharmaceutical composition further comprises a pharmaceutically acceptable carrier and / or a pharmaceutically acceptable excipient.

10. A pharmaceutical composition for treating renal cell carcinoma according to claim 8, characterized in that: The dosage form of the drug includes tablets, capsules, oral liquids, granules, suspensions, injections, powder injections, dripping pills, sustained-release preparations, controlled-release preparations or targeted preparations.

Citation Information

Patent Citations

  • Combinations of RIPK1- and IKK-inhibitors for the prevention or treatment of immune diseases

    CN111670049A

  • Bifunctional compositions for the treatment of cancer

    CN112672741A

  • Molecular profiling for cancer

    US20180045727A1

  • Modulating biomarkers to increase tumor immunity and improve the efficiacy of cancer immunotherapy

    WO2018148378A1

Cited By

  • Intermediate silk protein as biomarker for predicting stage, prognosis and drug resistance of renal clear cell carcinoma and application of intermediate silk protein

    CN119846209A